Global Pharmaceutical Contract Sales Organizations Market Size study & Forecast, by Service (Personal Promotion, Non-personal Promotion), by End-use (Pharmaceutical Companies, Biopharmaceutical Companies) and Regional Analysis, 2022-2029

Global Pharmaceutical Contract Sales Organizations Market Size study & Forecast, by Service (Personal Promotion, Non-personal Promotion), by End-use (Pharmaceutical Companies, Biopharmaceutical Companies) and Regional Analysis, 2022-2029

Global Pharmaceutical Contract Sales Organizations Market is valued at approximately USD 7.90 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 8.4% over the forecast period 2022-2029. In order to expand the production capacity for vaccinations and other efficient treatment alternatives, the pharmaceutical sector has come under scrutiny. These advances are being used by market participants in the pharmaceutical contract sales outsourcing (CSO) sector to meet consumer and healthcare facility demand. Another significant factor generating income prospects for industry participants in the pharmaceutical contract sales outsourcing (CSO) sector is the increased knowledge of the immune system's potential. A rising desire for lower in-house sales costs, a rise in pharmaceutical R&D activities, and a rising number of new medication launches are a few of the major drivers of the industry's expansion. Moreover, high government initiatives and rising geriatric population are creating a lucrative growth opportunity for the market over the forecast period 2022-2029.

Companies that make biopharmaceuticals are currently concentrating on enhancing their research capacities. Almost 45% of all drugs in development in 2022, as per the Pharma R&D annual review, were biopharmaceuticals. It is anticipated that biopharmaceutical companies will outsource their sales activities to CSOs so they may concentrate on their research capabilities due to the great interest these companies have in research. However, the high cost of Pharmaceutical Contract Sales Organizations stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Pharmaceutical Contract Sales Organizations Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2022, North America had the largest market share, accounting for approximately 34.45% of global industry revenue. One of the main factors promoting the region's growth is the existence of a sizable number of CSOs there, including IQVIA, Inc., EPS Corp., and Axxelus. The demand for pharmaceutical CSOs is further supported by the region's embrace of new technology for pharmaceutical sales and a sizable number of new drug launches in the area. During the projected period, the Asia Pacific region is anticipated to increase at the fastest rate. The demand for CSO operations in the region is rising as a result of the substantial number of pharmaceutical and biopharmaceutical businesses in the area that are consistently developing novel treatments. In comparison to other developed areas, the region offers CSO services at a lower cost; this is anticipated to improve CSO activities and assist the sector market.

Major market player included in this report are:
CMIC Holdings Co., Ltd.
Axxelus
EPS Corp.
QFR Solutions
MaBico
Mednext Pharma Pvt. Ltd.
Peak Pharma Solutions Inc.
IQVIA, Inc.
Promoveo Health
Syneous Health

Recent Developments in the Market:
Dr Reddy's Laboratories and IQVIA, Inc. entered a partnership in September 2022. In accordance with the agreement, IQVIA gave Dr Reddy access to its Orchestrated Customer Engagement (OCE) platform to support its CRM activities. According to the deal, Dr Reddy gave IQVIA's OCE application to all of its marketing users and field staff in India so they could more effectively engage customers by integrating marketing, account management, medical scientific liaison, sales, and other activities.

Global Pharmaceutical Contract Sales Organizations Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Service, End-use, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Service offerings of key players.

The detailed segments and sub-segment of the market are explained below:
By Service:
Personal Promotion
Non-personal Promotion
By End-use:
Pharmaceutical Companies
Biopharmaceutical Companies

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Companies Mentioned
CMIC Holdings Co., Ltd.
Axxelus
EPS Corp.
QFR Solutions
MaBico
Mednext Pharma Pvt. Ltd.
Peak Pharma Solutions Inc.
IQVIA, Inc.
Promoveo Health
Syneous Health

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.